ABSTRACT
Background: COVID-19 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was declared Pandemic by the World Health Organization on January 30, 2020. Vaccination represents the best possibility to resolve this pandemic. The current global challenge is the immunization against the SARS-CoV-2. However, the adverse events following immunization (AEFI) of the corona vaccine remains unclear. Aim and Objectives: This observational study aims to represent an accountable data of the AEFI between Covaxin and Covishield in North Indian population. Materials and Methods: The hospital-based prospective and observational study was employed from January 2021 to December 2021 for detecting and monitoring of AEFI in adults. All population vaccinated either covishield or covaxin with both doses were enrolled in the study as targeted population. Post-vaccination vaccinated population were telephonic follow-up with prior consent. Results: A total of 1015 vaccinated individuals were included in this study for assessment of AEFI. After statistical analysis of AEFI between both vaccination at 24 h P = 0.13, 3–7 days 0.4 and complete AEFI P = 0.06 observed. There is no association that was found significant P < 0.05 with the incidence of AEFI. Conclusion: The short-term outcome has not attribute any serious AEFI. This study demonstrated that both vaccines were well-tolerated and safe in generalized population. [ FROM AUTHOR] Copyright of Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research) is the property of Journal of Cardiovascular Disease Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
COVID-19;Covishield;Covaxin;Immunization;Adverse Events Following Immunization INTRODUCTION COVID-19 also known as novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was declared Pandemic by the World Health Organization (WHO) and a Public Health Emergency of International Concern on January 30, 2020. Data Collection Pertinent medical history of the vaccinated population was collected, including name, age, sex, complete address, phone number, batch number, and date of vaccination, as well as the site of simultaneous vaccination. Description of various reported combined covishield first and second dose AEFI after vaccination is separated with the number of patients suffered with a particular adverse events- fever (75%), pain at injection site (32%), headache (23%), weakness (3%), body pain (29%), vomiting (4.5%), myalgia (2%), nausea (1%), cough (2.6%), red patches (2%), cramps (2%), chills (25%), diarrhea (3%), dizziness (7%), loss of appetite (6%), hypertension (0.52%), tachycardia (3%), flushing (1.2%), drowsiness (6%), restlessness (0.65%), stomach pain (2%), and fatigue (17%). [...]description of various reported combined covaxin first and second dose AEFI after vaccination is separated with the number of patients suffered with a particular adverse events - fever (63%), pain at injection site (30%), headache (22%), weakness (5%), body pain (50%), vomiting (2%), myalgia (2%), nausea (2.5%), cough (8%), red patches (2%), cramps (3.5%), chills (27%), diarrhea (2%), dizziness (5%), loss of appetite (4%), hypertension (2%), tachycardia (1.75%), flushing (1%), drowsiness (7%), restlessness (3%), stomach pain (4%), and fatigue (11%) illustrated in Figure 1.